Durability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment

This cohort study examines the durability of immune response from BNT162b2 vaccination for severe acute respiratory syndrome coronavirus 2 in patients with cancer vs healthy controls.

Detalles Bibliográficos
Autores principales: Eliakim-Raz, Noa, Massarweh, Amir, Stemmer, Amos, Stemmer, Salomon M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358809/
https://www.ncbi.nlm.nih.gov/pubmed/34379092
http://dx.doi.org/10.1001/jamaoncol.2021.4390
_version_ 1783737418113875968
author Eliakim-Raz, Noa
Massarweh, Amir
Stemmer, Amos
Stemmer, Salomon M.
author_facet Eliakim-Raz, Noa
Massarweh, Amir
Stemmer, Amos
Stemmer, Salomon M.
author_sort Eliakim-Raz, Noa
collection PubMed
description This cohort study examines the durability of immune response from BNT162b2 vaccination for severe acute respiratory syndrome coronavirus 2 in patients with cancer vs healthy controls.
format Online
Article
Text
id pubmed-8358809
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-83588092021-08-12 Durability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment Eliakim-Raz, Noa Massarweh, Amir Stemmer, Amos Stemmer, Salomon M. JAMA Oncol Research Letter This cohort study examines the durability of immune response from BNT162b2 vaccination for severe acute respiratory syndrome coronavirus 2 in patients with cancer vs healthy controls. American Medical Association 2021-08-11 2021-11 /pmc/articles/PMC8358809/ /pubmed/34379092 http://dx.doi.org/10.1001/jamaoncol.2021.4390 Text en Copyright 2021 Eliakim-Raz N et al. JAMA Oncology. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Research Letter
Eliakim-Raz, Noa
Massarweh, Amir
Stemmer, Amos
Stemmer, Salomon M.
Durability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment
title Durability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment
title_full Durability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment
title_fullStr Durability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment
title_full_unstemmed Durability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment
title_short Durability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment
title_sort durability of response to sars-cov-2 bnt162b2 vaccination in patients on active anticancer treatment
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358809/
https://www.ncbi.nlm.nih.gov/pubmed/34379092
http://dx.doi.org/10.1001/jamaoncol.2021.4390
work_keys_str_mv AT eliakimraznoa durabilityofresponsetosarscov2bnt162b2vaccinationinpatientsonactiveanticancertreatment
AT massarwehamir durabilityofresponsetosarscov2bnt162b2vaccinationinpatientsonactiveanticancertreatment
AT stemmeramos durabilityofresponsetosarscov2bnt162b2vaccinationinpatientsonactiveanticancertreatment
AT stemmersalomonm durabilityofresponsetosarscov2bnt162b2vaccinationinpatientsonactiveanticancertreatment

Ejemplares similares